Plain-English translation of NCT07090499 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new cancer medication called designed to attack cancer cells. The medication is an 'antibody drug conjugate'—a type of therapy that acts like a guided missile, attaching to cancer cells and destroying them from within. Researchers want to learn whether this treatment is safe and how well it works in people with advanced cancers of the bladder, lungs, head and neck, esophagus, or pancreas.
People with advanced cancers in these areas often have limited treatment options after standard therapies stop working or stop being effective. This medication represents a new approach that may offer hope for patients who need additional treatment options.
You likely qualify if…
You likely don't qualify if…
You will receive the medication through an IV infusion in your arm at regular clinic visits. The study has multiple parts: first, researchers will test different doses to find the safest level, then they will confirm that dose works well in larger groups of patients organized by cancer type. Throughout the trial, you'll have blood tests, scans, and clinic visits to monitor how you're responding and check for side effects.
AI-generated summary from trial data · Sep 20, 2026 · Not medical advice
United States